Leigh Goedeke, PhD will review translational nonhuman primate models of nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome, sharing data demonstrating the therapeutic effects of a Controlled-Release Mitochondrial Protonophore (CRMP).

Nonalcoholic fatty liver disease (NAFLD), a condition in which fatty acids accumulate in the liver, can lead to potentially serious conditions including nonalcoholic steatohepatitis (NASH) and type-2 diabetes (T2D). While caloric restriction has been shown to be effective in humans, the strict dietary requirements can be very difficult to maintain in the long-term. Novel therapies are therefore required to reverse NAFLD, insulin resistance and diabetes.

In this webinar hosted by CrownBio, Dr. Leigh Goedeke of Yale University will discuss the development of controlled-release mitochondrial protonophore (CRMP) treatments for NAFLD and type-2 diabetes in diet-induced NHP models of obesity. In addition, she will present data supporting the safety and therapeutic effects of CRMP, including the reversal of hypertriglyceridemia, fatty liver, and hepatic inflammation.

Key Topics Include:

  • The translational relevance of NHP models of NAFLD and metabolic syndrome
  • How Controlled-Release Mitochondrial Protonophores (CRMPs) reduce dyslipidemia and glucose production
  • Study data demonstrating the therapeutic effects of CRMP treatment for NAFLD and type 2 diabetes
  • How Positional Isotopomer NMR Tracer Analysis (PINTA) is used to assess hepatic mitochondrial metabolism

Who Should Attend?

  • Preclinical scientists interested in learning more about CRMP and PINTA
  • Pharmacological researchers interested in therapies for NAFLD/NASH or type 2 diabetes
  • Scientists using NHPs or large animal models to study NAFLD/NASH


Postdoctoral Fellow
Yale School of Medicine

Production Partner

Crown Bioscience

Crown Bioscience brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, inflammation, cardiovascular, and metabolic disease. Our premier Translational Platforms help our clients accelerate their new drug development programs.

Additional Content From Crown Bioscience

Related Content